AMRX supply chain intelligence for Amneal Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Amneal Pharmaceuticals, Inc. (AMRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| DIRECT-CUSTOMER-SOLUTIONS-LLC | DIRECT-CUSTOMER-SOLUTIONS-LLC | 85% | the Company entered into a master logistics services agreement with Direct Customer Solutions, LLC |
| CHRS | Coherus Oncology, Inc. | 72% | Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimburs… |
| RDY | Dr. Reddy's Laboratories Limited | 72% | Reciprocal relationship from RDY graph: Reciprocal relationship from AMRX graph: Reciprocal relationship from RDY graph: Reciprocal relationship from AMRX graph: Reciprocal relationship from RDY grap… |
| SPRY | ARS Pharmaceuticals, Inc. | 72% | Reciprocal relationship from SPRY graph: Reciprocal relationship from AMRX graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from AMRX graph: Reciprocal relationship from SPRY g… |
| VERA | Vera Therapeutics, Inc. | 62% | Reciprocal relationship from VERA graph: Reciprocal relationship from AMRX graph: Reciprocal relationship from VERA graph: Reciprocal relationship from AMRX graph: Reciprocal relationship from VERA g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ALKS | Alkermes plc | 85% | Reciprocal relationship from ALKS graph: Reciprocal relationship from AMRX graph: pment purchase Property, plant and equipment $ — $ 160 Alkermes Plc Inventory and cost of goods sold $ — $ 92 26 The … |
| ALKS | Alkermes plc | 85% | pment purchase Property, plant and equipment $ — $ 160 Alkermes Plc Inventory and cost of goods sold $ — $ 92 26 The following table summarizes the amounts due to or from the Company for related part… |
| APACE-PACKAGING-LLC | APACE-PACKAGING-LLC | 85% | pment purchase Property, plant and equipment $ — $ 160 Alkermes Plc Inventory and cost of goods sold $ — $ 92 26 The following table summarizes the amounts due to or from the Company for related part… |
| AVTAR-INVESTMENTS-LLC | AVTAR-INVESTMENTS-LLC | 85% | pment purchase Property, plant and equipment $ — $ 160 Alkermes Plc Inventory and cost of goods sold $ — $ 92 26 The following table summarizes the amounts due to or from the Company for related part… |
| AZATECH-PHARMA-LLC | AZATECH-PHARMA-LLC | 85% | pment purchase Property, plant and equipment $ — $ 160 Alkermes Plc Inventory and cost of goods sold $ — $ 92 26 The following table summarizes the amounts due to or from the Company for related part… |
| KANAN-LLC | KANAN-LLC | 85% | pment purchase Property, plant and equipment $ — $ 160 Alkermes Plc Inventory and cost of goods sold $ — $ 92 26 The following table summarizes the amounts due to or from the Company for related part… |
| TRACY-PROPERTIES-LLC | TRACY-PROPERTIES-LLC | 85% | pment purchase Property, plant and equipment $ — $ 160 Alkermes Plc Inventory and cost of goods sold $ — $ 92 26 The following table summarizes the amounts due to or from the Company for related part… |
| CHRS | Coherus Oncology, Inc. | 72% | Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimburs… |
| RDY | Dr. Reddy's Laboratories Limited | 72% | Reciprocal relationship from RDY graph: Reciprocal relationship from AMRX graph: Reciprocal relationship from RDY graph: Reciprocal relationship from AMRX graph: Reciprocal relationship from RDY grap… |
| SPRY | ARS Pharmaceuticals, Inc. | 72% | Reciprocal relationship from SPRY graph: Reciprocal relationship from AMRX graph: Reciprocal relationship from SPRY graph: . We believe that NARCAN’s widespread use clearly demonstrates market uptake… |
| ACTAVIS-ELIZABETH-LLC | ACTAVIS-ELIZABETH-LLC | 62% | Business United States Department of Justice Investigations On May 15, 2023, Amneal Pharmaceuticals LLC (“Amneal”) received a Civil Investigative Demand (“CID”) from the Civil Division of the United … |
| AMNEAL-PHARMACEUTICALS-LLC | AMNEAL-PHARMACEUTICALS-LLC | 62% | Business United States Department of Justice Investigations On May 15, 2023, Amneal Pharmaceuticals LLC (“Amneal”) received a Civil Investigative Demand (“CID”) from the Civil Division of the United … |
| CAMBER-PHARMACEUTICALS-INC | CAMBER-PHARMACEUTICALS-INC | 62% | ern District of New York (the “USAO”) relating to similar topics concerning the Company’s suspicious order monitoring program and its compliance with the Controlled Substances Act. The Company has be… |
| DIXON-SHANE-LLC | DIXON-SHANE-LLC | 62% | ern District of New York (the “USAO”) relating to similar topics concerning the Company’s suspicious order monitoring program and its compliance with the Controlled Substances Act. The Company has be… |
| IMPAX-LABORATORIES-LLC | IMPAX-LABORATORIES-LLC | 62% | Business United States Department of Justice Investigations On May 15, 2023, Amneal Pharmaceuticals LLC (“Amneal”) received a Civil Investigative Demand (“CID”) from the Civil Division of the United … |
| KASHIV-BIOSCIENCES-LLC | KASHIV-BIOSCIENCES-LLC | 62% | fer materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to: • risks related to our proposed transaction to acquire membership i… |
| TAKEDA-PHARMACEUTICALS-U-S-A-INC | TAKEDA-PHARMACEUTICALS-U-S-A-INC | 62% | ern District of New York (the “USAO”) relating to similar topics concerning the Company’s suspicious order monitoring program and its compliance with the Controlled Substances Act. The Company has be… |
| TEVA | Teva Pharmaceutical Industries Limited | 62% | Reciprocal relationship from TEVA graph: Reciprocal relationship from AMRX graph: Reciprocal relationship from TEVA graph: Reciprocal relationship from AMRX graph: Business United States Department o… |
| TEVA-PHARMACEUTICALS-USA-INC | TEVA-PHARMACEUTICALS-USA-INC | 62% | Business United States Department of Justice Investigations On May 15, 2023, Amneal Pharmaceuticals LLC (“Amneal”) received a Civil Investigative Demand (“CID”) from the Civil Division of the United … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| AMRX-DEBT | Debt stack $2.6B | 90% | Market cache reports total debt of $2.6B. |
| AMRX-DEBT-7745 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2019-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| AMRX-OWNER-DIMENSIONAL-FUND-ADVISORS-LP | DIMENSIONAL FUND ADVISORS LP | 95% | 13F/ownership overlay lists DIMENSIONAL FUND ADVISORS LP; shares held 5,690,586; value $70.7B; as of 2026-03-31. |
| AMRX-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 95% | 13F/ownership overlay lists VANGUARD CAPITAL MANAGEMENT LLC; shares held 15,170,068; value $188.6B; as of 2026-03-31. |
| AMRX-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 95% | 13F/ownership overlay lists MORGAN STANLEY; shares held 12,958,365; value $153.4B; as of 2026-03-31. |
| AMRX-OWNER-TPG-GP-A-LLC | TPG GP A, LLC | 95% | 13F/ownership overlay lists TPG GP A, LLC; shares held 12,328,767; value $153.2B; as of 2026-03-31. |
| AMRX-OWNER-VANGUARD-PORTFOLIO-MANAGEMENT-LLC | VANGUARD PORTFOLIO MANAGEMENT LLC | 95% | 13F/ownership overlay lists VANGUARD PORTFOLIO MANAGEMENT LLC; shares held 11,324,933; value $140.8B; as of 2026-03-31. |
| AMRX-OWNER-RUBRIC-CAPITAL-MANAGEMENT-LP | Rubric Capital Management LP | 95% | 13F/ownership overlay lists Rubric Capital Management LP; shares held 11,037,589; value $137.2B; as of 2026-03-31. |
| AMRX-OWNER-STATE-STREET-CORP | STATE STREET CORP | 95% | 13F/ownership overlay lists STATE STREET CORP; shares held 6,794,702; value $84.5B; as of 2026-03-31. |
| AMRX-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | GEODE CAPITAL MANAGEMENT, LLC | 95% | 13F/ownership overlay lists GEODE CAPITAL MANAGEMENT, LLC; shares held 4,546,048; value $56.5B; as of 2026-03-31. |
| AMRX-OWNER-GOLDMAN-SACHS-GROUP-INC | GOLDMAN SACHS GROUP INC | 95% | 13F/ownership overlay lists GOLDMAN SACHS GROUP INC; shares held 5,444,935; value $68.1B; as of 2026-03-31. |
| AMRX-OWNER-BLACKROCK-INC | BlackRock, Inc. | 95% | 13F/ownership overlay lists BlackRock, Inc.; shares held 24,519,192; ownership 7.68%; value $304.8B; as of 2026-03-31. |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | ANDREW S BOYER | Executive Vice President | option_exercise | 65359 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | Patel Chintu | Co-CEO | option_exercise | 354031 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | Konidaris Tasos | Executive Vice President & CFO | option_exercise | 72622 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | Shah Nikita | Executive Vice President | option_exercise | 65359 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | Patel Chirag K. | President & Co-CEO | option_exercise | 354031 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | Patel Tushar Bhikhubhai | grant | 12763469 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | Daly Jason B. | EVP, Chief Legal Officer | option_exercise | 65359 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | Konidaris Tasos | Executive Vice President & CFO | option_exercise | 72622 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | Shah Nikita | Executive Vice President | option_exercise | 65359 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | Patel Chirag K. | President & Co-CEO | option_exercise | 354031 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | Patel Chintu | Co-CEO | option_exercise | 354031 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | ANDREW S BOYER | Executive Vice President | option_exercise | 65359 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | Shah Nikita | Executive Vice President | sell | 183853 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | Boyer Andrew S | Executive Vice President | option_exercise | 397554 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | Shah Nikita | Executive Vice President | sell | 183853 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | Boyer Andrew S | Executive Vice President | option_exercise | 397554 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | Konidaris Tasos | Executive Vice President & CFO | option_exercise | 458716 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | Daly Jason B. | EVP, Chief Legal Officer | option_exercise | 305810 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | Patel Chirag K. | President & Co-CEO | sell | 15616 shares |
| AMRX | Amneal Pharmaceuticals, Inc. | 82% | Patel Chintu | Co-CEO | sell | 17112 shares |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| SPRY | ARS Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| TEVA | Teva Pharmaceutical Industries Limited | 100.00 | 1 | ['customer'] |
| RDY | Dr. Reddy's Laboratories Limited | 100.00 | 1 | ['customer', 'supplier'] |
| ALKS | Alkermes plc | 100.00 | 1 | ['customer'] |
| CHRS | Coherus Oncology, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| VERA | Vera Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| ALK | Alaska Air Group, Inc. | 50.00 | 2 | |
| ALVO | Alvotech | 50.00 | 2 | |
| CLYM | Climb Bio, Inc. | 50.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 50.00 | 2 | |
| ORANY | ORANGE | 50.00 | 2 | |
| CRNT | Ceragon Networks Ltd. | 50.00 | 2 | |
| CAH | Cardinal Health, Inc. | 50.00 | 2 | |
| DERM | Journey Medical Corporation | 50.00 | 2 | |
| ATR | AptarGroup, Inc. | 50.00 | 2 | |
| IMMP | Immutep Limited | 50.00 | 2 | |
| COYA | Coya Therapeutics, Inc. | 50.00 | 2 | |
| BMY | Bristol-Myers Squibb Company | 50.00 | 2 | |
| BMYMP | Bristol-Myers Squibb Co | 50.00 | 2 | |
| BAC | Bank of America Corporation | 50.00 | 2 |